Table 1.
Indications | n |
---|---|
Follow-up of known massesa | 924 |
Follow-up of nonpituitary tumors | 4 |
Suspected mass | |
Prolactinoma | 455 |
ACTH adenoma | 349 |
Nonfunctioning adenoma/mass | 103 |
GH adenoma | 39 |
TSH adenoma | 20 |
Metastases to pituitary | 18 |
FSH/LH functioning adenoma | 11 |
Sarcoidosis | 2 |
Endocrinological work-up | |
Hypogonadism | 247 |
Hypopituitarism | 128 |
GH deficiency | 41 |
Hypothyroidism | 34 |
Adrenal insufficiency | 32 |
Diabetes insipidus | 18 |
MEN1 syndrome | 17 |
Postpartum | 8 |
SIADH | 6 |
Neurological symptoms | |
Headache | 75 |
Visual loss/blurring | 24 |
Bitemporal hemianopsia | 15 |
Altered mental status | 5 |
Syncope | 5 |
Homonymous hemianopsia | 5 |
Diplopia | 3 |
Seizure | 3 |
Trauma | 3 |
CVA/TIA | 2 |
Meningitis | 1 |
Cranial neuropathy (III, IV, VI) | 1 |
Total | 2598 |
MEN1, Multiple endocrine neoplasia 1; SIADH, syndrome of inappropriate antidiuretic hormone; CVA, cerebrovacular accident; TIA, transient ischemic attack.
Includes incidentalomas discovered on prior x-rays, CT, or MRI scans and undiagnosed masses.